Stocks

TROY, Mich., May 14, 2025 (GLOBE NEWSWIRE) -- Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Personal Lines production was up 22% for the periodNet income allocable …

DALLAS, May 14, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced its financial …

Revenue for the First Quarter Ended March 31, 2025 was$13.1million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now …

NEW YORK, May 14, 2025--(BUSINESS WIRE)--New Fortress Energy Inc. (Nasdaq: NFE) ("NFE" or the "Company") today announced the completion of the sale of its assets and operations in Jamaica to Excelerate Energy, Inc. (NYSE: EE) ("Excelerate") for $1.055 billion. The transaction was initially announced …

On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts …

Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World’s First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 …

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with …